Evidence map›Paper›PMID 33784944›Full record

ArticleJournal of biomolecular structure & dynamics2022

Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.

Zahra Khorsandi, Maral Afshinpour, Fatemeh Molaei, Rafee Habib Askandar, Fariba Keshavarzipour, Maryam Abbasi, Hojjat Sadeghi-Aliabadi

Abstract read
In one paragraph

Article in Journal of biomolecular structure & dynamics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zahra KhorsandiDepartment of Chemistry, Isfahan University of Technology, Isfahan, Iran.
Maral AfshinpourBioinformatics Lab., Department of Biology, School of Sciences, Razi University, Kermanshah, Iran.
Fatemeh MolaeiDepartment of Anaesthesiology, Facility of Paramedical, Jahrom University of medical science, Jahrom, Iran.
Rafee Habib AskandarResearch Center, Sulaimani Polytechnic University, Sulaimani, Iraq.
Fariba KeshavarzipourIsfahan Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Maryam AbbasiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.ORCID 0000-0002-3022-2507
Hojjat Sadeghi-AliabadiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In response to the current pandemic caused by the novel SARS-CoV-2, we design new compounds based on Lopinavir structure as an FDA-approved antiviral agent which is currently under more evaluation in clinical trials for COVID-19 patients. This is the first example of the preparation of Lopinavir isosteres from the main core of Lopinavir conducted to various heterocyclic fragments. It is proposed that main protease inhibitors play an important role in the cycle life of coronavirus. Thus, the protease inhibition effect of synthesized compounds was studied by molecular docking method. All of these 10 molecules, showing a good docking score compared. Molecular dynamics (MD) simulations also confirmed the stability of the best-designed compound in Mpro active site.Communicated by Ramaswamy H. Sarma.

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesCoronavirus Protease InhibitorsCysteine EndopeptidasesDipeptidesEthylenesHumansLopinavirMolecular Docking SimulationMolecular Dynamics SimulationProtease InhibitorsAntiviral AgentsCoronavirus 3C ProteasesCoronavirus Protease InhibitorsCysteine EndopeptidasesDipeptidesEthyleneshydroxyethyleneLopinavirphenylalanylphenylalanineProtease InhibitorsCovid-19lopinavirmolecular dockingmolecular dynamic simulationsynthesis

Identifiers

PMID33784944
PMCPMC8022343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.